IL6 and cholestasis: For the first time, we demonstrated that it is not the extent but the duration of the elevation of the inflammation-associated proteins CrP and IL-6 that determines the risk of cholestasis and neurodevelopmental delay in this patient group regardless of the underlying disease, i.e., NEC, SIP or MI.